533 related articles for article (PubMed ID: 30793770)
1. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
2. Upregulated miR-155 in papillary thyroid carcinoma promotes tumor growth by targeting APC and activating Wnt/β-catenin signaling.
Zhang X; Li M; Zuo K; Li D; Ye M; Ding L; Cai H; Fu D; Fan Y; Lv Z
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1305-13. PubMed ID: 23796566
[TBL] [Abstract][Full Text] [Related]
3. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
[TBL] [Abstract][Full Text] [Related]
4. FOXE1 inhibits cell proliferation, migration and invasion of papillary thyroid cancer by regulating PDGFA.
Ding Z; Ke R; Zhang Y; Fan Y; Fan J
Mol Cell Endocrinol; 2019 Aug; 493():110420. PubMed ID: 31129275
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
Zhou Z; Liu Y; Ma M; Chang L
Biomed Pharmacother; 2017 Dec; 96():98-103. PubMed ID: 28965013
[TBL] [Abstract][Full Text] [Related]
6. FOXN3 suppresses the growth and invasion of papillary thyroid cancer through the inactivation of Wnt/β-catenin pathway.
Zhao C; Mo L; Li C; Han S; Zhao W; Liu L
Mol Cell Endocrinol; 2020 Sep; 515():110925. PubMed ID: 32619584
[TBL] [Abstract][Full Text] [Related]
7. SOX18 exerts tumor-suppressive functions in papillary thyroid carcinoma through inhibition of Wnt/β-catenin signaling.
Geng Q; Deng H; Fu J; Cui F
Exp Cell Res; 2020 Nov; 396(1):112249. PubMed ID: 32858034
[TBL] [Abstract][Full Text] [Related]
8. CircRNA circRNA_102171 promotes papillary thyroid cancer progression through modulating CTNNBIP1-dependent activation of β-catenin pathway.
Bi W; Huang J; Nie C; Liu B; He G; Han J; Pang R; Ding Z; Xu J; Zhang J
J Exp Clin Cancer Res; 2018 Nov; 37(1):275. PubMed ID: 30424816
[TBL] [Abstract][Full Text] [Related]
9. LncRNA PTCSC3/miR-574-5p Governs Cell Proliferation and Migration of Papillary Thyroid Carcinoma via Wnt/β-Catenin Signaling.
Wang X; Lu X; Geng Z; Yang G; Shi Y
J Cell Biochem; 2017 Dec; 118(12):4745-4752. PubMed ID: 28513866
[TBL] [Abstract][Full Text] [Related]
10. KCNIP3 silence promotes proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma through activating Wnt/β-catenin pathway.
Zhong J; Lin R; Wang G; Lin L; Ruan S; Liu W
Tissue Cell; 2022 Apr; 75():101739. PubMed ID: 35066335
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
Cho SW; Kim YA; Sun HJ; Ahn HY; Lee EK; Yi KH; Oh BC; Park DJ; Cho BY; Park YJ
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1641-9. PubMed ID: 24848709
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of CSN6 attenuates papillary thyroid carcinoma progression by reducing Wnt/β-catenin signaling and sensitizes cancer cells to FH535 therapy.
Wen D; Liao T; Ma B; Qu N; Shi RL; Lu ZW; Wang YL; Wei WJ; Ji QH
Cancer Med; 2018 Feb; 7(2):285-296. PubMed ID: 29341469
[TBL] [Abstract][Full Text] [Related]
13. Novel LncRNA AK023507 inhibits cell metastasis and proliferation in Papillary Thyroid Cancer through β-catenin/Wnt Signaling Pathway.
Yang M; Huang S; Zhao Y; Xie B; Hu X; Cai Y
Biochem Biophys Res Commun; 2023 May; 655():104-109. PubMed ID: 36934585
[TBL] [Abstract][Full Text] [Related]
14. SDC4 Gene Silencing Favors Human Papillary Thyroid Carcinoma Cell Apoptosis and Inhibits Epithelial Mesenchymal Transition
Chen LL; Gao GX; Shen FX; Chen X; Gong XH; Wu WJ
Mol Cells; 2018 Sep; 41(9):853-867. PubMed ID: 30165731
[TBL] [Abstract][Full Text] [Related]
15. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
16. CDK5RAP3 acts as a putative tumor inhibitor in papillary thyroid carcinoma via modulation of Akt/GSK-3β/Wnt/β-catenin signaling.
Feng X; Jiang J; Sun L; Zhou Q
Toxicol Appl Pharmacol; 2022 Apr; 440():115940. PubMed ID: 35219640
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma.
Li JY; Han C; Zheng LL; Guo MZ
Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318
[TBL] [Abstract][Full Text] [Related]
18. ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells.
Qiu W; Yang Z; Fan Y; Zheng Q
Tumour Biol; 2016 Sep; 37(9):12665-12672. PubMed ID: 27448298
[TBL] [Abstract][Full Text] [Related]
19. LncRNA FALEC promotes proliferation, migration, and invasion of PTC cells through regulating Wnt/β-catenin signaling pathway.
Xiao X; Li L; Cui JC; Wang Y
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4361-4367. PubMed ID: 32373973
[TBL] [Abstract][Full Text] [Related]
20. Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.
Bychkov A; Saenko V; Nakashima M; Mitsutake N; Rogounovitch T; Nikitski A; Orim F; Yamashita S
Thyroid; 2013 Jul; 23(7):817-28. PubMed ID: 23327367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
